Table 1.
Patient demographics. TMZ – temozolomide, PCV – procarbazine, lomustine (CCNU) and vincristine, Ph – photon therapy, H+ – proton therapy.
| study A | study B | study A + B | |||
|---|---|---|---|---|---|
| Number of patients [n] | |||||
| total/male/female | 24/11/13 | 67/38/29 | 91/49/42 | ||
| Age at baseline [years] | |||||
| mean ± std | 45.6 ± 14.5 | 54.7 ± 13.9 | 52.3 ± 14.5 | ||
| range [min – max] | [20.1 – 76.7] | [23.2 – 81.8] | [20.1 – 81.8] | ||
| Glioma grade [n] | |||||
| grade I/II/III/IV | 1/3/13/7 | 0/0/0/67 | 1/3/13/74 | ||
| RTx treatment [n] | |||||
| Ph/H+/mix | 4/19/1 | 48/19/0 | 52/38/1 | ||
| Chemotherapy [n] | |||||
| TMZ/PCV/none | 7/5/12 | 67/0/0 | 74/5/12 | ||
| Follow-ups | |||||
| mean number of follow-ups [n] | 4.4 ± 3.0 | 3.6 ± 3.2 | 3.8 ± 3.2 | ||
| mean follow-up period [days] | 444.8 ± 311.4 | 422.2 ± 438.5 | 428.1 ± 407.3 | ||
| range follow-up period [days] | [85 – 1073] | [63 – 1874] | [63 – 1874] | ||